Morgan Stanley Transcode Therapeutics, Inc. Transaction History

Morgan Stanley

  • $1.35 Trillion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$0.33 - $984.0 $384 - $1.15 Million
1,165 New
1,165 $0

Others Institutions Holding RNAZ

# of Institutions
1
Shares Held
6.5K
Call Options Held
0
Put Options Held
0
View Full List

About Transcode Therapeutics, Inc.

RNAZ Quotes by TradingView
  • Ticker RNAZ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,977,200
  • Market Cap $4.93M
  • Description
  • TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs incl...
More about RNAZ
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email